Category 1, 2 and 3: what the FDA labels actually mean
Almost every headline about peptides "becoming legal" confuses three different regulatory states. Here is the plain-English version, and the distinction that decides whether your pharmacy can actually make the thing.
The setting: what 503A compounding is#
A 503A pharmacy compounds medicines for one named patient at a time, under a prescription. To do that with a bulk drug substance that isn't part of an FDA-approved product, the substance generally needs to appear on the FDA's 503A bulk drug substances list. The categories are how the agency sorts candidates while it decides.
The three categories, plainly#
| Category | What it means | Practical effect |
|---|---|---|
| Category 1 | Nominated substances that meet the criteria for evaluation and raise no significant safety risk identified so far. | Pharmacies may generally compound with them while FDA completes its review — the workable state. |
| Category 2 | Substances the agency has flagged with significant safety risks. | Effectively off-limits for compounding. This is the list 19 peptides landed on in 2023. |
| Category 3 | Nominated without adequate supporting information to evaluate. | Not usable pending real data — an administrative dead end rather than a safety judgment. |
The distinction almost everyone gets wrong#
Enforcement discretion — FDA saying it does not intend to act against a pharmacy — attaches only to Category 1. When FDA removed 12 peptides from Category 2 in April 2026, they were not moved to Category 1. They landed on no list at all, which carries no enforcement discretion, the same practical position as Category 2. FDA's updated category list, published 14 May 2026, confirms this by omission.
This is the single most misreported fact of 2026, and almost every "peptides are legal now" headline rests on it.
The list that actually has force of law#
The categories are non-binding interim guidance. The binding instrument is the 503A Bulks List at 21 C.F.R. § 216.23(a), and it currently contains 6 substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, thymol iodide.
Why the 12 came off — and it was not a safety finding#
The 12 came off Category 2 because the NOMINATORS WITHDREW their nominations — not because FDA reassessed safety. FDA's July 2026 briefing document names the withdrawing parties and states FDA proceeded to the advisory committee anyway. That matters because "FDA reconsidered the risk" and "the people who asked for the review stopped asking" are very different stories, and only the second one happened.
What PCAC is, and what its votes are worth#
The Pharmacy Compounding Advisory Committee is an advisory body. It reviews nominated substances and recommends; the FDA decides. In July 2026 the committee recommended six of seven reviewed peptides for the 503A list — including BPC-157 on a narrow 8–6 vote — over FDA staff recommendations against inclusion. That divergence is unusual and worth holding in mind: an advisory recommendation the agency's own scientists opposed is not a settled outcome.
The committee voted against Emideltide (DSIP). Five more peptides are scheduled for review before the end of February 2027, though no date has been announced as of 2026-09-06.
The third lane: research use only#
Separate from all of the above sits the RUO market — substances sold labelled "for research use only." That lane is legally distinct from compounding: RUO products are not approved for human use, vendors may not make clinical claims or provide human dosing guidance, and the label is doing legal work rather than describing a quality standard. Most of what consumers actually buy in the peptide world comes from here, which is why we cover it as journalism and never link a vendor.
What actually changed for consumers in 2026 — and what didn't#
- Changed: the political posture. HHS leadership publicly backed broader peptide access in February 2026, and agency action followed within seven weeks.
- Changed: 12 peptides lost their Category 2 "significant safety risk" designation — a reputational and procedural change, not a legal permission.
- Changed: an advisory committee recommended six peptides for the compounding list, over the objections of FDA's own reviewers.
- Changed, and this is the only concrete one: GHK-Cu was restored to Category 1 for non-injectable routes on 14 May 2026. It is the one peptide of the 19 a pharmacy can actually compound today.
- Not changed: no peptide became an FDA-approved drug. Approval was never on the table in this process.
- Not changed: no peptide was added to the binding bulks list. It still holds six substances, none of them peptides.
- Not changed: nothing new became legal to compound. The 12 removed peptides get no enforcement discretion because they are on no list.
- Not changed: the evidence base. No new trials were produced by any of this.
- Not changed: the RUO market is still the RUO market — unapproved for human use regardless of what the compounding lists do.
Two more things that will decide whether this actually lands#
Rulemaking, not a vote. Adding anything to the bulks list requires notice-and-comment rulemaking. Law-firm estimates run 12–24 months or longer; as of 2026-09-06 no proposed rule has published.
The ingredient bottleneck nobody mentions. Even a favorable final rule would not be enough. 21 U.S.C. § 353a also requires the active ingredient to come from an FDA-registered establishment with a valid certificate of analysis. Most peptide ingredient is made by facilities that are not FDA-registered. So even a favorable final rule could leave pharmacies turning prescriptions away for want of compliant material.
Worth knowing about the committee itself: the same advisory committee construct rejected every peptide put to it in October and December 2024. It was reconstituted in mid-2026, and the reconstituted panel recommended six of seven. Reporting on that change has raised conflict-of-interest questions we have not independently verified, so we note the sequence and leave the inference to you.
Watch and listen#
Independent third-party material we found genuinely useful. Embedding is not endorsement, we have no relationship with these creators, and any commercial conflicts we know of are labelled. Video players load only when you press play, though the still image comes from Google; a podcast embed loads its player when it scrolls into view. What that means for you.
Peptide regulatory news#
PCAC voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A Bulks List on narrow margins (BPC-157 8–6); DSIP was voted down. FDA staff had recommended against inclusion, and the committee is advisory — the FDA's final call is still pending.
Our Legal-Status Tracker, updated →The most-watched peptide of the reclassification clears its first regulatory hurdle. Category 2 removal is separate from 503A compounding eligibility — two different tracks.
The two-track explainer →The reversal of the 2023 restrictions began here. The FDA's formal updated list remains unpublished; every row of our tracker updates the day it drops.
The Legal-Status Tracker →All tracked news → · Subscribe to this beat (RSS) · Fed by a daily automated scan; entries publish only after primary-source verification.
Regulatory explainer, not medical or legal advice. Compounded peptides are not FDA-approved drugs; RUO compounds are not approved for human use. Status changes fast — the tracker carries dates and sources per row, and updates the day primary documents publish.